Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Non-Current Deffered Revenue (2019 - 2025)

AC Immune has reported Non-Current Deffered Revenue over the past 4 years, most recently at $2.9 million for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 43.78% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, down 43.78% year-over-year, with the annual reading at $2.9 million for FY2025, 43.78% down from the prior year.
  • Non-Current Deffered Revenue was $2.9 million for Q4 2025 at AC Immune, down from $3.4 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $102.9 million in Q1 2021 and troughed at $2.9 million in Q4 2025.
  • The 3-year median for Non-Current Deffered Revenue is $5.4 million (2024), against an average of $23.5 million.
  • The largest YoY upside for Non-Current Deffered Revenue was 24.02% in 2025 against a maximum downside of 43.78% in 2025.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $33.8 million in 2021, then crashed by 84.58% to $5.2 million in 2024, then tumbled by 43.78% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Non-Current Deffered Revenue are $2.9 million (Q4 2025), $3.4 million (Q3 2025), and $4.3 million (Q2 2025).